Radiopaque polymers

A polymer according to any preceding claim in which W is independently selected from —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1—(C═O)—O—C1-4alkyl and —O—(C═O)C1-4alkyl or a group —BZ, wherein

• B is a bond, a C1 to 6 branched or non branched alkanediyl group or a branched or non branched C1-6 oxyalkylene group;
• and
• Z is a group of formula II
• Wherein A3 and A4, are the same or different and are selected from —O, —S, and —NH—;
• and —W1+ is —W2—N+R43, in which W2 is C1-6 alkanediyl and R4 are the same or different and each is hydrogen or C1-4 alkyl;
• and
• wherein —OH, COOH, —OPO3H2 and —SO3H maybe in the form of a pharmaceutically acceptable salt.

A polymer according to any preceding claim comprising PVA wherein the PVA comprises pendant groups of the formula:

• Wherein
• W is independently selected from —OH, —COOH, —SO3H, —O—(C2H5O)qR1 or —O—(C1-4alkyl)R2;
• q is 1, 2 or 3;
• n is 1, 2 or 3;
• R1 is H or (C1-4alkyl);
• and R2 is —COOH or —SO3H;
• and
• wherein —SO3H, —COOH and phenolic —OH, maybe in the form of a pharmaceutically acceptable salt.

A compound of the formula VIII

• Where
• M is —CHO, —C(OH)OR20 or —C(OR21)OR20;
• wherein R20 and R21 are independently selected from C1-6 alkyl;
• R22 is H, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkyl-R2, —(C2H5O)qR1 or —(C═O) C1-4alkyl;
• or is a group of the formula —BZ;
• wherein B is a bond or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents;
• and Z is a zwitterionic ammonium, phosphonium, or sulphonium phosphate or phosphonate ester group;
• R1 is H or C1-4 alkyl;
• R2 is —COOH, —SO3H, or —OPO3H2;
• q is an integer from 1 to 4;
• and
• X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S;
• wherein —COOH, —OPO3H2, —SO3H and the phenolic —OH, maybe in the form of a pharmaceutically acceptable salt.

A compound of the formula IX:

• Where
• M is —CHO, —C(OH)OR20 or —C(OR21)OR20;
• wherein R20 and R21 are independently selected from C1-6 alkyl;
• and
• R23 is C1-4alkyl, C1-4hydroxyalkyl, C1-4alkyl-R2, —(C2H5O)qR1 or —(C═O) C1-4alkyl;
• or is a group of the formula —BZ;
• wherein B is a bond or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents;
• and Z is a zwitterionic ammonium, phosphonium, or sulphonium phosphate or phosphonate ester group;
• R1 is H or C1-4 alkyl;
• R2 is —COOH, —SO3H, or —OPO3H2;
• X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S;
• and
• wherein —COOH, —OPO3H2 and —SO3H, maybe in the form of a pharmaceutically acceptable salt.

A compound of the formula X:

• Wherein:
• M is —CHO, —C(OH)OR20 or —C(OR21)OR20;
• wherein R20 and R21 are independently selected from C1-6 alkyl;
• and
• R24 is H, C1-4alkyl, C1-4hydroxyalkyl, C1-4alkyl-R2, —(C2H5O)qR1 or —(C═O) C1-4alkyl;
• or is a group of the formula —BZ;
• wherein B is a bond or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents;
• B is preferably a bond or a C1 to 6 branched or non branched alkanediyl group such as a methylene, ethylene propylene or butylene group;
• and Z is a zwitterionic ammonium, phosphonium, or sulphonium phosphate or phosphonate ester group as described in further detail herein;
• R1 is H or C1-4 alkyl;
• R2 is —COOH, —SO3H, or —OPO3H2;
• X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S;
• and
• wherein —COOH, —OPO3H2, —SO3H and the phenolic —OH, maybe in the form of a pharmaceutically acceptable salt.

A compound of the formula XI:

• Wherein:
• M is —CHO, —C(OH)OR20 or —C(OR21)OR20;
• wherein R20 and R21 are independently selected from C1-6 alkyl;
• preferably methyl and
• R26 and R27 are the same or different and each independently selected from the group consisting of —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1—(C═O)—O—C1-4alkyl and —O—(C═O)C1-4alkyl;
• or, alternatively W may be a zwitterionic group of the formula —BZ
• wherein —SO3H, —COOH and phenolic —OH, maybe in the form of a pharmaceutically acceptable salt;
• wherein B is a bond or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents;
• B is preferably a bond or a C1 to 6 branched or non branched alkanediyl group such as a methylene, ethylene propylene or butylene group;
• and
• Z is a zwitterionic ammonium, phosphonium, or sulphonium phosphate or phosphonate ester group as described in further detail herein.
• R1 is H or C1-4 alkyl;
• R2 is —COOH, —SO3H, or —OPO3H2;
• and
• Wherein —COOH, —OPO3H2, —SO3H and the phenolic —OH, maybe in the form of a pharmaceutically acceptable salt.